Fennec Pharmaceuticals Inc — Cash Flow (NASDAQ:FENC) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities 15.6 M14.22 M18.06 M17.14 M26.98 M 5.04 M Cash from investing activities ————— — Cash from financing activities 32.29 M4.98 M20.73 M6.64 M13.62 M 14.04 M Free cash flow 15.6 M14.22 M18.06 M17.14 M26.98 M 5.04 M

Nouvelles

Certara, Inc. (CERT) Q4 Earnings Lag Estimates

Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates

Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026 (NASDAQ:FENC)

City of Hope to study PEDMARK for hearing protection in testicular cancer

Pedmark livre une étude au Japon - Moins de perte auditive, même puissance dans la lutte contre le cancer | Benzinga France

Fennec’s pediatric hearing protection drug shows positive results in Japan

Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power - Fennec Pharmaceuticals (NASDAQ:FENC)

Fennec Pharmaceuticals repays all outstanding convertible notes

Fennec Pharmaceuticals raises $5 million in non-brokered offering

Fennec Pharmaceuticals raises $40.25 million through public offering

Fennec Pharmaceuticals plans $5 million share offering to existing investors

Fennec Pharmaceuticals prices $35 million public offering